Tailored vaccine shows promise in preventing cancer return
NCT ID NCT07504484
First seen Apr 04, 2026 · Last updated Apr 30, 2026 · Updated 5 times
Summary
This early-phase study tested a personalized immunotherapy (neoantigen vaccine) in 6 patients with stage III colorectal or non-small cell lung cancer after they completed standard surgery and chemotherapy. The goal was to see if the vaccine is safe and can help prevent the cancer from coming back. Results suggest the treatment is well tolerated, but more research is needed to confirm its effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.